Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis

OBJECTIVES: To investigate the prevalence of dyslipoproteinemia in a homogeneous cohort of polyarticular juvenile idiopathic arthritis patients. METHODS: Based on the National Cholesterol Education Program, fasting lipoprotein levels and risk levels for coronary artery disease were determined in 28 patients with polyarticular juvenile idiopathic arthritis. The exclusion criteria included diabetes, thyroid dysfunction, smoking, proteinuria, lipid-lowering drugs, and hormone/diuretic therapy. Disease activity, disease duration, and therapy with corticosteroids and/or chloroquine were defined at the time of lipid measurements. RESULTS: Dyslipoproteinemia was identified in 20 of the 28 (71%) patients with polyarticular juvenile idiopathic arthritis. The primary lipoprotein risk factor was decreased high-density lipoprotein cholesterol (57%), followed by elevated levels of low-density lipoprotein cholesterol (18%), triglycerides (14%), and total cholesterol (7%). The male patients had decreased high-density lipoprotein cholesterol levels than the female patients (p<0.05). The incidence of decreased high-density lipoprotein cholesterol levels did not seem to be affected by disease activity or therapy because the incidence was similar in patients with active or inactive disease, with or without corticosteroid use and with or without chloroquine use. In addition, the frequency of decreased high-density lipoprotein cholesterol levels was similar in patients with short (&#8804;5 years) vs. long (>5 years) disease duration. CONCLUSIONS: Dyslipoproteinemia is highly prevalent in patients with polyarticular juvenile idiopathic arthritis and is primarily related to decreased high-density lipoprotein cholesterol levels; therefore, early intervention is essential

Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.

BackgroundThere are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated interstitial lung disease (SSc-ILD).MethodsPrimary objectives were safety and pharmacokinetics. Secondary outcomes included clinical assessments, quantitative high-resolution computed tomography (HRCT) of the chest, serum biomarker assays and skin biopsy-based gene expression subset assignments. Clinical response was defined as decrease of &gt;5 or &gt;20% from baseline in the modified Rodnan Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169.ResultsDasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No significant changes in clinical assessments or serum biomarkers were seen at six months. By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39% showed no progression of total ILD. Among 12 subjects with available baseline and post-treatment skin biopsies, three were improvers and nine were non-improvers. Improvers mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improvers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory gene expression subset was associated with higher baseline HRCT score (p = 0.0556). Non-improvers showed significant increase in lung fibrosis (p = 0.0313).ConclusionsIn patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile but no significant clinical efficacy. Patients in the inflammatory gene expression subset showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis during the study. These findings suggest that target tissue-specific gene expression analyses can help match patients and therapeutic interventions in heterogeneous diseases such as SSc, and quantitative HRCT is useful for assessing clinical outcomes.Trial registrationClinicaltrials.gov NCT00764309

Study of pulmonary vasculopathy in the collagen V-induced systemic sclerosis experimental model

A esclerodermia sistêmica (ES) é caracterizada por fibrose da pele e órgãos internos, ativação imunológica e vasculopatia. Os modelos animais de ES sofrem com a falta de uma prova definitiva para o envolvimento vascular observado na doença humana. Um novo modelo induzido por colágeno do tipo V (COLV) reproduz muitas características da ES como fibrose e fenômenos imunológicos. No entanto, o estudo da vasculopatia ainda não foi abordado. O objetivo desse estudo foi investigar as alterações estruturais e funcionais das células endoteliais das artérias pulmonares do modelo de ES induzido pelo COLV, assim como determinar a doença pulmonar com ênfase especial no depósito de colágeno e síntese de RNAm de colágenos. Coelhos fêmeas Nova Zelândia (n = 8) foram imunizados com COLV humano emulsificado em adjuvante de Freund ou apenas com adjuvante de Freund (controle; n = 8). Após 7, 75 e 210 dias, os animais foram sacrificados e os pulmões foram analisados por microscopia eletrônica, hematoxilina e eosina, e marcações especiais incluindo imunomarcação para neovascularização (CD31), apoptose de células endoteliais (induzida pela caspase-3) e atividade endotelial (endotelina-1 e VEGF). A resposta vascular a acetilcolina (Ach) foi estudada em anéis de artéria pulmonar isolada. Para determinar o conteúdo de colágeno, expressão RNAm dos colágenos I, III e V e quantidade de colágeno (hidroxiprolina aminoácido específico), os pulmões foram submetidos a imunofluorescência, PCR em tempo real e análise bioquímica. Foi observado que os coelhos imunizados com COLV apresentaram um aumento progressivo de apoptose e atividade das células endoteliais a partir de 7 dias quando comparados aos coelhos controle (p 0,01). Em contrapartida, apenas aos 210 dias os coelhos imunizados com COLV apresentaram aumento significativo na neovascularização quando comparados com o grupo controle (p < 0,001). Coincidente com esses achados, a microscopia eletrônica mostrou alterações das células endoteliais caracterizada por apoptose, alterações degenerativas das organelas e tumefação citoplasmática. As células endoteliais pareciam estar destacadas da membrana basal. Os coelhos imunizados com COLV de 210 dias necessitaram de uma dose maior de Ach do que os controles para alcançar o relaxamento máximo de 50% (EC50) dos anéis de artéria pulmonar (p = 0,02). Por fim, foi observado que os coelhos de 210 dias imunizados com COLV apresentaram uma intensa expressão de COLV no interstício broncovascular, acompanhado de um aumento na expressão do RNAm (p < 0,001) quando comparado ao grupo controle. Os coelhos imunizados com COLV apresentaram uma maior quantidade de conteúdo de colágeno, quando comparados com os controles, nos diferentes tempos estudados (p < 0,01). Este estudo fornece evidência para a disfunção pulmonar do endotélio vascular em coelhos com ES induzida pelo COLV. As alterações observadas, nesse estudo, reforçam o papel do endotélio como evento patogênico primário na ES. Desta forma, o modelo ES induzido pelo COLV pode fornecer informações importantes sobre a patogênese da doença humanaThe hallmarks of systemic sclerosis (SSc) are fibrosis of skin and internal organs, immune activity and vasculopathy. Animal models of SSc suffer from lack of a definitive evidence for vascular involvement observed in human disease. A novel model induced by collagen type V (COLV) reproduces many features of SSc, however vascular study has not been addressed. The aim of the present study was therefore evaluate pulmonary arteries for structural and functional alterations in endothelial cells in the COLV-induced SSc model, as well as determine the lung disease with special emphasis on collagen deposition and mRNA collagen synthesis. Female New Zealand rabbits (n = 8) were immunized with human COLV/Freund´s adjuvant or Freund´s adjuvant alone (control; n = 8). After 7, 75 and 210 days, the animals were sacrificed and the lungs were examined by electron microscopy, hematoxylin&eosin and special stains including immunostaining for neovascularization (CD31), endothelial cells apoptosis (caspase-3 induced) and endothelial activity (endothelin-1 and VEGF). Vascular response to acetylcholine (Ach) on isolated pulmonary artery rings was evaluated. To determine collagen content, mRNA expressions of COL I, III and V, and the quantity of collagen-specific amino acid hydroxyproline, the lungs were submitted to immunofluorescence, real-time qPCR and biochemical examination. The COLV rabbits demonstrated an endothelial cells apoptosis and activity compared to control rabbits starting at day-7 (p 0.01). A significant increase in neovascularization was observed only in the COLV-rabbits at day-210 (p < 0,001). Coincident with these findings, the electron microscopy revealed extensive endothelial cells abnormalities characterized by apoptosis, degenerative organelle changes and cytoplasmic tumefaction. Endothelial cells appeared to be detached from the basement membrane. Ach dose required to achieve 50% maximum relaxation (EC50) of pulmonary artery rings was increased in COLV rabbits at day-210 (p = 0.02). The content of hydroxyproline was increased in COLV rabbits compared with that observed in control rabbits, at the different days studied (p < 0,01). Ultimately, the COLV rabbits at 210-day showed an intense expression of COLV in the bronchovascular interstitium, followed by a markedly up-regulation of COLV mRNA (p < 0.001) as compared to controls. This study provides evidence for pulmonary vascular endothelial cell dysfunction in rabbits with COLV-induced SSc. The findings of this study reinforce the role of endothelial cells as a primary pathogenic event in SSc. The COLV model may provide insight into the pathogenesis of human diseas

Brazilian lyme-like disease or baggio-yoshinari syndrome: exotic and emerging brazilian tick-borne zoonosis

A Doença de Lyme (DL) é uma zoonose frequente no hemisfério Norte e considerada uma enfermidade infecciosa causada por espiroquetas do complexo Borrelia burgdorferi sensu lato e transmitida pela picada de carrapatos do grupo Ixodes ricinus. Os primeiros casos semelhantes à DL no Brasil foram descobertos, em 1992, em irmãos que após serem picados por carrapatos desenvolveram eritema migratório, sintomas gripais e artrite. Criteriosa análise da casuística brasileira, mostrou que os aspectos epidemiológicos, clínicos e laboratoriais no país, divergiam bastante dos exibidos pelos pacientes com DL nos Estados Unidos da América e Eurásia. Não foram encontrados carrapatos do complexo Ixodes ricinus hematófago ao homem nas áreas de risco; a enfermidade no país é recorrente; a Borrelia burgdorferi jamais foi isolada no Brasil e os ensaios sorológicos específicos exibem positividade baixa e oscilante. Além disso, o exame do sangue periférico dos pacientes quando analisados à microscopia eletrônica exibe estruturas sugestivas de Mycoplasma spp, Chlamydia spp e bacteroides. Na verdade, estas estruturas podem representar as formas latentes das espiroquetas (forma L ou bactérias desprovidas de parede), adaptadas a sobreviver em condições inóspitas em hospedeiros vertebrados e invertebrados. Assim, a zoonose presente no país recebeu a denominação de Síndrome Baggio-Yoshinari e definida como: "Enfermidade infecciosa nova e emergente brasileira, transmitida por carrapatos não pertencentes ao complexo Ixodes ricinus, causada por espiroquetas na sua morfologia atípica e latente, que origina manifestações clínicas semelhantes às observadas na DL, exceto pela ocorrência de recidivas clínicas e desordens autoimunes".Lyme disease (LD) is a frequent zoonosis found in the Northern Hemisphere and is considered an infectious disease caused by spirochetes belonging sensu lato to the Borrelia burgdorferi complex transmitted by ticks of the Ixodes ricinus group. In 1992, first cases similar to LD were described in Brazil, when brothers, after a tick bite episode developed symptoms , as erythema migrans, general flu-like symptoms and arthritis. Careful analysis of Brazilian LD-like illness casuistry showed that epidemiological, clinical and laboratorial features in the country were very different from those exhibited by North American and Eurasian LD patients. Human blood-suckers Ixodes ricinus complex ticks were absent at risk areas; the disease is recurrent in the country; Borrelia burgdorferi was never isolated in Brazil and specific serologic tests have shown little positivity with inconsistent results. Furthermore, peripheral blood analysis of patients on electron microscopy exhibited structures resembling Mycoplasma spp, Chlamydia spp and spirochete-like microorganisms. In fact, they were assumed to be latent forms of spirochetes (L form or cell wall deficient bacteria) adapted to survive at inhospitable conditions in vertebrate and invertebrate hosts. For these reasons, the Brazilian zoonosis was named Baggio-Yoshinari Syndrome (BYS) and defined as: "Exotic and emerging Brazilian infectious disease, transmitted by ticks not belonging to the Ixodes ricinus complex, caused by latent spirochetes with atypical morphology, which originates LD-like symptoms, except for occurrence of relapsing episodes and auto-immune disorders".Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Ministério da Saúd

Primeiro caso de febre maculosa brasileira branda associada à artrite

Descrevemos o primeiro caso brasileiro de Riquetsiose branda, agravada por monoartrite em joelho, em adulto jovem picado por carrapato na perna esquerda na regi&#227;o de Camburi, localizada no munic&#237;pio de S&#227;o Sebasti&#227;o, sul da regi&#227;o costeira do estado de S&#227;o Paulo, Mata Atl&#226;ntica, Brasil. O paciente apresentou uma escara de inocula&#231;&#227;o no local da picada do carrapato, associada ao aumento ganglionar em virilha esquerda, febre, poliartralgia, cefaleia e erup&#231;&#227;o macular. Vinte dias ap&#243;s o epis&#243;dio da picada de carrapato, o paciente apresentou monoartrite em joelho direito. O diagn&#243;stico de Riquetsiose branda foi estabelecido pela an&#225;lise imunol&#243;gica sequencial em amostras de soro e l&#237;quido sinovial, tendo sido empregada a t&#233;cnica de imunofluoresc&#234;ncia (IF) indireta para anticorpos reativos contra Rickettsia parkeri e Rickettsia rickettsii. A Riquetsiose branda &#233; uma zoonose emergente, que deve ser investigada pelos m&#233;dicos, incluindo reumatologistas, em pacientes que apresentem erup&#231;&#227;o macular, febre e, eventualmente, artrite, ap&#243;s visita ao sul da regi&#227;o costeira da Mata Atl&#226;ntica no Brasil

Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.

BackgroundThere are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated interstitial lung disease (SSc-ILD).MethodsPrimary objectives were safety and pharmacokinetics. Secondary outcomes included clinical assessments, quantitative high-resolution computed tomography (HRCT) of the chest, serum biomarker assays and skin biopsy-based gene expression subset assignments. Clinical response was defined as decrease of &gt;5 or &gt;20% from baseline in the modified Rodnan Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169.ResultsDasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No significant changes in clinical assessments or serum biomarkers were seen at six months. By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39% showed no progression of total ILD. Among 12 subjects with available baseline and post-treatment skin biopsies, three were improvers and nine were non-improvers. Improvers mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improvers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory gene expression subset was associated with higher baseline HRCT score (p = 0.0556). Non-improvers showed significant increase in lung fibrosis (p = 0.0313).ConclusionsIn patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile but no significant clinical efficacy. Patients in the inflammatory gene expression subset showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis during the study. These findings suggest that target tissue-specific gene expression analyses can help match patients and therapeutic interventions in heterogeneous diseases such as SSc, and quantitative HRCT is useful for assessing clinical outcomes.Trial registrationClinicaltrials.gov NCT00764309

Baseline demographics and disease characteristics of SSc patients (n = 31).

<p>Baseline demographics and disease characteristics of SSc patients (n = 31).</p

Representative pairs of baseline and follow-up HRCT images.

<p>(A) Better case: pulmonary fibrosis (PF) improved and ground glass opacity (GGO) worsened by the visual assessment in whole lung; (B) annotated HRCT of (A) with a CAD system: QLF and QILD in whole lung decreased, by 2.9% (3.9% to 1.0%) and 0.2% (19.9% to 19.7%), respectively. (C) Stable case; (D) annotated CAD of (C): QLF in the worst lobe (lower left) increased by 2% (64% to 66%). In whole lung, QLF and QILD increased, by 2.3% (39.5% to 41.8%) and 1.8% (72.4% to 74.2%), respectively. (E) Worse case: PF worsened and GGO improved; (F) annotated CAD of (E): QLF increased by 6.0% (28% to 34%) in the most severe lobe (lower right) and 1.8% (9.8% to 11.6%) in whole lung. QILD in whole lung was stable (41.3% to 40.5%).</p

HRCT trends across improvers and non-improvers.

<p>(A) QGG trends. (B) QLF trends. (C) Baseline [QGG-QLF] marker vs. intrinsic subset. (D) Baseline [QGG-QLF] marker vs. response status.</p